Although aminoglycosides remain an essential part of therapy of severe gram-negative infections in critically ill patients, the use of extended-interval aminoglycoside dosing (EIAD) in this population is highly controversial. The rationale for EIAD is based on major pharmacodynamic characteristics of the aminoglycosides, which include concentration-dependent bactericidal effects, postantibiotic effect, and adaptive resistance. Alterations in the pharmacokinetics of aminoglycosides in the critically ill have been well documented, including changes in both drug distribution and elimination. These pharmacokinetic alterations may prevent critically ill patients from realizing the potential benefits of EIAD by reducing serum concentrations achieved by recommended EIAD regimens and may perhaps place patients at risk of therapeutic failure. Although numerous studies of EIAD have been conducted, there is a lack of data specifically concerning the efficacy and safety of EIAD in the critically ill. The most appropriate methods for monitoring EIAD in this population are also not clearly established. There are thus many questions regarding the suitability of EIAD in the critically ill. This article briefly reviews the rationale for EIAD and data related to the pharmacokinetics, efficacy, safety, and clinical monitoring of EIAD in critically ill patients. Considerations and recommendations for use of EIAD in the critically ill are provided.
Hustinx WNM, Hoepelman IM. Aminoglycoside dosage regimens. Is once a day enough?Clin Pharmacokinet. 1993;25:427-432.
4.
Bates RD, Nahata MC. Once-daily administration of aminoglycosides. Ann Pharmacother. 1994;28:757-766.
5.
Preston SL, Briceland LL. Single daily dosing of aminoglycosides. Pharmacotherapy. 1995;15:297-316.
6.
Lacy MK, Nicolau DP, Nightingale CH, et al. The pharmacodynamics of aminoglycosides. Clin Infect Dis. 1998;27:23-27.
7.
Anderson ET, Young LS, Hewitt WL. Simultaneous antibiotic levels in “breakthrough” gram-negative rod bacteremia. Am J Med. 1976;61:493-497.
8.
Moore RD, Smith CR, Littman PS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis. 1984;149:443-448.
9.
Moore RD, Smith CR, Littman PS. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med. 1984;77:657-662.
10.
Moore RD, Littman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987;155:93-99.
11.
Blaser J, Stone BB, Groner MC, et al. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother. 1987;31:1054-1060.
12.
Zhanel GG, Craig WA. Pharmacokinetic contributions to postantibiotic effects. Focus on aminoglycosides. Clin Pharmacokinet. 1994;27:377-392.
13.
Daikos GL, Lolans VT, Jackson GG. First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use. Antimicrob Agents Chemother. 1991;35:117-123.
Tran Ba Huy P, Deffrennes D.Aminoglycoside ototoxicity: influence of dosage regimen on drug uptake and correlation between membrane binding and some clinical features. Acta Otolaryngol. 1988;105:511-515.
Galloe AM, Gaudal N, Christensen HR, et al. Aminoglycosides: single or multiple daily dosing? A meta-analysis on efficacy and safety. Eur J Clin Pharmacol. 1995;48:39-43.
18.
Barza M, Ioannidis JPA, Cappelleri JC, et al. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ. 1996;312:338-345.
19.
Munckhof WJ, Grayson JL, Turnidge JD. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother. 1996;37:645-663.
20.
Ferriols-Lisart R, Alos-Alminana M.Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. Am J Health-Syst Pharmacol. 1996;53:1141-1150.
21.
Freeman CD, Strayer AH. Mega-analysis of meta-analysis: an examination of meta-analysis with an emphasis on once-daily aminoglycoside comparative trials. Pharmacotherapy. 1996;16:1093-1102.
22.
Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med. 1996;124:717-725.
23.
Bailey TC, Little JR, Littenberg B, et al. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis. 1997;24:786-795.
24.
Ali MZ, Goetz MB. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis. 1997;24:796-809.
25.
Hatala R, Dinh TT, Cook DJ. Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review. Clin Infect Dis. 1997;24:810-815.
26.
Summer WR, Michael JR, Lipsky JJ. Initial aminoglycoside levels in the critically ill. Crit Care Med. 1983;11:948-950.
27.
Flint LM, Gott J, Short L, et al. Serum level monitoring of aminoglycoside antibiotics. Limitations in intensive care unit-related bacterial pneumonia. Arch Surg. 1985;120:99-103.
28.
Niemiec PW Jr, Allo MD, Miller CF. Effect of altered volume of distribution on aminoglycoside levels in patients in surgical intensive care. Arch Surg. 1987;122:207-212.
29.
Hassan E, Ober JD. Predicted and measured aminoglycoside pharmacokinetic parameters in critically ill patients. Antimicrob Agents Chemother. 1987;31:1855-1858.
30.
Mann HJ, Fuhs DW, Awang R, et al. Altered aminoglycoside pharmacokinetics in critically ill patients with sepsis. Clin Pharmacol. 1987;6:148-153.
31.
Beckhouse MJ, Whyte IM, Byth PL, et al. Altered aminoglycoside clearance in the critically ill. Anaesth Intensive Care. 1988;16:418-422.
32.
Dasta JF, Armstrong DK. Variability in aminoglycoside pharmacokinetics in critically ill surgical patients. Crit Care Med. 1988;16:327-330.
33.
Townsend PL, Fink MP, Stein KL, et al. Aminoglycoside pharmacokinetics: dosage requirements and nephrotoxicity in trauma patients. Crit Care Med. 1989;17:154-157.
34.
Hickling K, Begg E, Moore ML. A prospective randomized trial comparing individualized pharmacokinetic dosing prediction for aminoglycosides with prediction based on estimated creatinine clearance in critically ill patients. Intensive Care Med. 1989;15:233-237.
35.
Hickling KG, Begg EJ, Perry RE, et al. Serum aminoglycoside clearance is predicted as poorly by renal aminoglycoside clearance as by creatinine clearance in critically ill patients. Crit Care Med. 1991;19:1041-1047.
36.
Watling SM, Dasta JF. Aminoglycoside dosing considerations in intensive care unit patients. Ann Pharmacother. 1993;27:351-357.
37.
Tholl DA, Shikuma LR, Miller TQ, et al. Physiologic response of stress and aminoglycoside clearance in critically ill patients. Crit Care Med. 1993;21:248-251.
38.
Marik PE. Aminoglycoside volume of distribution and illness severity in critically ill septic patients. Anaesth Intensive Care. 1993;21:172-173.
39.
Pimentel FL, Abelha F, Trigo MA, et al. Determination of plasma concentrations of amikacin in patients of an intensive care unit. J Chemother. 1995;7:45-49.
40.
Dorman T, Thompson D, Trentler B, et al. Gentamicin: is loading with 3 mg/kg enough [abstract]. Crit Care Med. 1995;23(suppl):A259.
41.
Botha FJ, van der Bijl P, Seifart HI, et al. Fluctuation of the volume of distribution of amikacin and its effect on once-daily dosage and clearance in a seriously ill patient. Intensive Care Med. 1996;22:443-446.
42.
Dimick JB, Dorman T, Swoboda SM, et al. Is 4 mg/kg an adequate loading dose for gentamicin/tobramycin in critically ill surgical patients? [abstract 242]. Crit Care Med. 1999;27(suppl):A93.
43.
Tham L-S, Low C-L.A prospective evaluation of the predictive performance of an aminoglycoside pharmacokinetic program in Asian surgical intensive care patients [abstract 520/T108]. Crit Care Med. 2000;28(suppl):A171.
44.
Hoey L, Joslin S, Rotschafer J, et al. Wide variation in peak concentrations and length of aminoglycoside-free interval associated with single daily dose aminoglycoside regimens in 52 burn patients [abstract]. Crit Care Med. 1995;23(suppl):A258.
45.
Kluth V, Koch S.Alternative aminoglycoside dosing in neurointensive care unit (NICU) patients [abstract 213]. Crit Care Med. 1998;26(suppl):A99.
46.
Wolfe TA, Dasta JF, Reilley TE, et al. Assessment of the appropriateness of once-daily aminoglycoside dosing in surgical intensive care unit patients [abstract 214]. Crit Care Med. 1998;26(suppl):A99.
47.
Chapman SA, Wacksman GP. Intrapatient variability of aminoglycoside pharmacokinetic parameters in simulated extended-interval aminoglycoside dosing [abstract 241]. Crit Care Med. 1999;27(suppl):A93.
48.
Smith CJ, Marini CP, Ritter GS. Once-daily aminoglycoside dosing for critically ill patients with renal insufficiency [abstract 343]. Crit Care Med. 1999;27(suppl):A124.
49.
Brusco L Jr, Talbert S, Wedderburn RV. Once-daily aminoglycoside dosing protocol results in inadequate gentamicin levels in surgical intensive care unit patients with normal renal function [abstract 346]. Crit Care Med. 1999;27(suppl):A138.
50.
Dwivedi A, Jucha J, Czerwinski C, et al. Once-daily aminoglycoside dosing (7 mg/kg) in surgical ICU patients fails to achieve therapeutic target peak levels [abstract 347]. Crit Care Med. 1999;27(suppl):A138.
51.
Barletta JF, Johnson SB, Nix DE, et al. Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens. J Trauma Injury Infect Crit Care. 2000;49:869-872.
52.
Vaidyanathan S, Watt JW, Singh G, et al. Dosage of once-daily gentamicin in spinal cord injury patients. Spinal Cord. 2000;38:197-198.
53.
Shirk MB, Goyal A, Bhatt N, et al. Once daily aminoglycoside dosing (7 mg/kg) in the medical intensive care unit patient [abstract 519/T107]. Crit Care Med. 2000;28(suppl):A171.
54.
Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995;39:650-655.
55.
Demczar DJ, Nafziger AN, Bertino JS Jr. Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing. Antimicrob Agents Chemother. 1997;41:1115-1119.
56.
Prins JM, Bueller HR, Kuijper EJ, et al. Once versus thrice daily gentamicin in patients with serious infections. Lancet. 1993;341:335-339.
57.
Sturm AW. Netilmicin in the treatment of gram-negative bacteremia: single daily versus multiple daily dosage. J Infect Dis. 1989;159:931-937.
58.
Hansen M, Achen F, Carstensen C, et al. Once-versus thrice-daily dosing of netilmicin in febrile immunocompromised patients: a randomized, controlled study of efficacy and safety. J Drug Dev. 1988;1(suppl 3):119-124.
59.
Hollender LF, Bahnini J, De Manzini N, et al. A multicentric study of netilmicin once daily versus thrice daily in patients with appendicitis and other intra-abdominal infections. J Antimicrob Chemother. 1989;23:773-783.
60.
Nordstrom L, Ringberg H, Cronberg S, et al. Does administration of an aminoglycoside in a single daily dose affect its efficacy and safety?J Antimicrob Chemother. 1990;25:159-173.
French MA, Cerra FB, Plaut ME, et al. Amikacin and gentamicin accumulation pharmacokinetics and nephrotoxicity in critically ill patients. Antimicrob Agents Chemother. 1981;19:147-152.
63.
Schentag JJ, Cerra FB, Plaut ME. Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients. Antimicrob Agents Chemother. 1982;21:721-726.
64.
Jaresko GS, Boucher BA, Dole EJ, et al. Risk of renal dysfunction in critically ill trauma patients receiving aminoglycosides. Clin Pharmacol. 1989;8:43-48.
65.
Boucher BA, Coffey BC, Kuhl DA, et al. Algorithm for assessing renal dysfunction risk in critically ill trauma patients receiving aminoglycosides. Am J Surg. 1990;160:473-480.
66.
Cimino MA, Rotstein C, Slaughter RL, et al. Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy. Am J Med. 1987;83:1091-1097.
67.
Eisenberg JM, Koffer H, Glick HA, et al. What is the cost of nephrotoxicity associated with aminoglycosides?Ann Intern Med. 1989;107:900-909.
68.
Rybak MJ, Abate BJ, Kang SL, et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother. 1999;43:1549-1555.
69.
Olsen KM, Rudis M, Rebuck JA, et al. Effect of single daily dose vs. multiple daily dosing of tobramycin on alanine aminopeptidase and N-acetyl-β-D-glucosaminidase excretion [abstract 566/T154]. Crit Care Med. 2000;28(suppl):A185.
70.
Wong J, Brown G.Does once-daily dosing of aminoglycosides affect neuromuscular function?J Clin Pharm Ther. 1996;21:407-411.
71.
Gilbert DN. Aminoglycosides. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 5th ed.Philadelphia, PA: Churchill Livingstone; 2000:307-336.
72.
Periti P.Pharmacoeconomic evaluation of once-daily aminoglycoside treatment. J Chemother. 1995;7:380-394.
73.
Mithani H, Brown G.The economic impact of once-daily versus conventional administration of gentamicin and tobramycin. Pharmacoeconomics. 1996;10:494-503.
74.
Nicolau DP, Wu AHB, Finocchiaro S, et al. Once-daily aminoglycoside dosing: impact on requests and costs for therapeutic drug monitoring. Ther Drug Monit. 1996;18:263-266.
75.
Hitt CM, Klepser ME, Nightingale CH, et al. Pharmacoeconomic impact of once-daily aminoglycoside administration. Pharmacotherapy. 1997;17:810-814.
76.
Anaizi N.Once-daily dosing of aminoglycosides. A consensus document. Int J Clin Pharmacol Ther. 1997;35:223-226.
